目的:探讨甲磺酸多沙唑嗪片联合厄贝沙坦氢氯噻嗪片治疗高血压患者的临床效果。方法:回顾性选取2021年1 月—2023 年 9 月泉州市光前医院收治的 216 例高血压患者作为研究对象，根据治疗方案不同将患者分为对照组与研究组，各 108 例。单一厄贝沙坦氢氯噻嗪片治疗的设为对照组，甲磺酸多沙唑嗪片联合厄贝沙坦氢氯噻嗪片治疗的设为研究组。比较两组临床疗效、治疗前后血压变异性、血脂、血清细胞因子及不良反应。结果:研究组临床总有效率为 98。15%，高于对照组的 91。67%，差异有统计学意义(P＜0。05);治疗后，两组 24 h动脉收缩压变异性(24 h SBPV)、24 h动脉舒张压变异性(24 h DBPV)及血清C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、同型半胱氨酸(Hcy)水平降低，且研究组低于对照组，差异有统计学意义(P＜0。05);治疗后，两组血清甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平降低，且研究组低于对照组，两组高密度脂蛋白胆固醇(HDL-C)水平升高，且研究组高于对照组，差异有统计学意义(P＜0。05);研究组不良反应率为 8。33%，与对照组的 6。48%比较，差异无统计学意义(P＞0。05)。结论:甲磺酸多沙唑嗪片联合厄贝沙坦氢氯噻嗪片治疗高血压，可调节血压变异性，降低血脂、血清细胞因子水平，疗效显著，且安全性高。
Effect of Doxazosin Mesylate Tablets Combined with Irbesartan Hydrochlorothiazide Tablets in the Treatment of Patients with Hypertension
Objective:To study the clinical effect of Doxazosin Mesylate Tablets combined with Irbesartan Hydrochlorothiazide Tablets in the treatment of patients with hypertension.Method:A total of 216 patients with hypertension who admitted to Quanzhou Guangqian Hospital from January 2021 to September 2023 were retrospectively selected as the research objects,the patients were divided into control group and study group according to different treatment schemes,with 108 cases in each group.Patients treated with single Irbesartan Hydrochlorothiazide Tablets were set as the control group,and patients treated with Doxazosin Mesylate Tablets combined with Irbesartan Hydrochlorothiazide Tablets were set as study group.The clinical efficacy,blood pressure variability,blood lipids,serum cytokines before and after treatment and adverse reactions were compared between two groups.Result:The total clinical effective rate of the study group was 98.15%,which was higher than 91.67%of the control group,the difference was statistically significant(P＜0.05);after treatment,the levels of 24 h systolic blood pressure variability(24 h SBPV),24 h diastolic blood pressure variability(24 h DBPV),serum C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)and homocysteine(Hcy)in two groups were decreased,and those in the study group were lower than those in the control group,and the differences were statistically significant(P＜0.05);after treatment,the levels of serum triglyceride(TG),total cholesterol(TC)and low density lipoprotein cholesterol(LDL-C)in two groups were decreased,and those in the study group were lower than the control group,the levels of high density lipoprotein cholesterol(HDL-C)in two groups were increased,and that in the study group was higher than that in the control group,and the differences were statistically significant(P＜0.05);the adverse reaction rate of the study group was 8.33%,compared with 6.48%of the control group,the difference was not statistically significant(P＞0.05).Conclusion:Doxazosin Mesylate Tablets combined with Irbesartan Hydrochlorothiazide Tablets in the treatment of patients with hypertension can regulate blood pressure variability,reduce blood lipids and serum cytokine levels,with significant efficacy and high safety.
万方数据
维普
